In home PFT testing is now available to patients with ndd Medical’s mobile EasyOne Pro
ANDOVER, Mass. and San Clemente, CA— June 24, 2016--American Respiratory Labs (ARL), a California-based mobile pulmonary function testing company, is now able to perform sophisticated lung assessments in patients’ homes, thanks to portable PFT devices developed by ndd Medical Technologies, Inc.
Patients are no longer limited to having their PFT testing done in hospital-based labs. Thanks to ndd’s EasyOne PRO®, ARL patients like Jeanne R. of Anaheim, CA, can get any needed testing done in the comfort of her own home.
“Having the breathing test here was fantastic as far as I was concerned,” said Jeanne, 83. “I have family and they take me, but sometimes it’s not convenient for them. Going to the hospital by bus is a lot of work, and once there it’s hard going from room to room when you can’t breathe. Having the testing at home was very easy, comfortable and a lot less stressful.”
The EasyOne PRO performs DLCO testing, spirometry and full lung volumes anywhere in just 20 minutes. Because ARL personnel visit multiple homes each day – some of their clients live in third- and fourth-floor walkups— they need a device that is light, compact, and durable. EasyOne Pro, which measures 12-square-inches, fits the bill.
Another important factor in ARL’s choice of the EasyOne Pro was that the accurate, reliable ultrasound technology eliminates calibration and maintenance. The device is ready as soon as it is turned on.
After testing, software enables ARL to input PFT results into a patient’s electronic health record.
“Patients are happy and appreciative that we can do such comprehensive pulmonary function testing in their homes,” reports ARL owner Robin Contino. “Some people are not mobile and it can be an ordeal to get transportation to a PFT lab. Others are unable to afford transportation.”
At-home spirometry is often performed to assess a patient’s need for oxygen. DLCO testing can determine whether shortness of breath is caused by respiratory or cardiac disease, or to differentiate between asthma and COPD, for appropriate treatment.
The point of care (POC) testing that ARL offers is one of the fastest growing segments of clinical testing. The global POC market is expected to grow 9.3% annually from 2013 to 2018, and to reach $27.5 billion by 2018, according to MarketsandMarkets.